About BiondVax

BiondVax is a publicly traded biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.

BiondVax is currently conducting a phase IIb trial in collaboration with the EU consortium UNISEC. Please see here for more details.

BiondVax’s go-to-market strategy for its lead candidate M-001, universal flu vaccine is to initially obtain regulatory approval as a primer to a pandemic or seasonal vaccine, and following the accumulation of enough data, to gain approval as a universal standalone vaccine.

In the News

Channel1 thumbnailBiondVax CSO Dr. Tamar Ben-Yedidia on Israel Channel One news. [27 Dec. 2016]

Israel21C thumbnailIs this the end of flu? Israel’s BiondVax develops universal flu vaccine” [18 Feb. 2016]

Join our Mailing List